SLP Stock Overview
Develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SLP from our risk checks.
Simulations Plus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.58 |
| 52 Week High | US$51.22 |
| 52 Week Low | US$27.07 |
| Beta | 0.71 |
| 11 Month Change | -19.47% |
| 3 Month Change | -25.12% |
| 1 Year Change | -30.30% |
| 33 Year Change | -45.96% |
| 5 Year Change | -20.17% |
| Change since IPO | 1,905.82% |
Recent News & Updates
Recent updates
We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative
Nov 07
Simulations Plus: Declining Margins Are A Problem
Aug 22Simulations Plus: Steady Growth, But What About The Margins?
Jul 10Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts
May 14Why We're Not Concerned About Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price
Mar 29Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Feb 09Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI
Feb 01We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit
Jan 12Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Nov 06Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Sep 06Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Jun 28Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Feb 10With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case
Nov 23A Look At The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Oct 21Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Sep 19Shareholder Returns
| SLP | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -7.2% | -8.3% | -1.0% |
| 1Y | -30.3% | 5.7% | 30.3% |
Return vs Industry: SLP underperformed the US Healthcare Services industry which returned 7.1% over the past year.
Return vs Market: SLP underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SLP volatility | |
|---|---|
| SLP Average Weekly Movement | 5.8% |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SLP's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 245 | Shawn O'Connor | www.simulations-plus.com |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Simulations Plus, Inc. Fundamentals Summary
| SLP fundamental statistics | |
|---|---|
| Market cap | US$553.45m |
| Earnings (TTM) | US$9.95m |
| Revenue (TTM) | US$70.01m |
55.6x
P/E Ratio7.9x
P/S RatioIs SLP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLP income statement (TTM) | |
|---|---|
| Revenue | US$70.01m |
| Cost of Revenue | US$26.86m |
| Gross Profit | US$43.15m |
| Other Expenses | US$33.20m |
| Earnings | US$9.95m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 61.63% |
| Net Profit Margin | 14.22% |
| Debt/Equity Ratio | 0% |
How did SLP perform over the long term?
See historical performance and comparison